Welcome to our dedicated page for Aveanna Healthcare Holdings SEC filings (Ticker: AVAH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Aveanna Healthcare Holdings Inc. (AVAH) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Aveanna, a diversified home care platform headquartered in Atlanta, Georgia with locations in 38 states, uses these filings to report material events, financing arrangements, and financial results related to its pediatric and adult home-based healthcare services.
Among the key documents available are Current Reports on Form 8-K, where Aveanna describes material definitive agreements such as amendments to its first lien credit agreement, the creation and refinancing of term loan and revolving credit facilities, and the termination of a second lien credit agreement. Other 8-K filings report underwriting agreements for secondary offerings of common stock by existing stockholders, as well as the closing of those offerings.
Aveanna also uses Form 8-K to furnish press releases announcing quarterly and year-to-date financial results, preliminary financial data, and updated guidance. These filings often discuss non-GAAP measures such as EBITDA, Adjusted EBITDA, Normalized Adjusted EBITDA, Field contribution, Field contribution margin, Adjusted net income, and Adjusted net income per diluted share, along with reconciliations to GAAP metrics. Additional 8-K items address board and governance matters, including amendments to stockholders’ agreements and changes in board composition.
On Stock Titan, users can view these AVAH filings alongside AI-powered summaries that explain the main points of each document in plain language. Real-time updates from EDGAR help surface new 8-Ks and, when filed, periodic reports such as annual reports on Form 10-K, quarterly reports on Form 10-Q, and proxy statements. The platform also highlights insider-related filings like Form 4 when available, allowing investors to review reported transactions by directors and officers in the context of Aveanna’s broader regulatory and financial disclosures.
An affiliate of AVAH filed a Rule 144 notice to sell 52,100 shares of common stock through Morgan Stanley Smith Barney, with an aggregate market value of $413,153.00, on or around February 19, 2026 on NASDAQ.
The notice reports that these shares come from restricted stock vesting on February 14, 2026, when 136,204 shares of common stock were acquired from the issuer. It also discloses a prior sale of 36,015 shares of common stock in the past three months, generating $292,488.62 in gross proceeds. The filing states that the person relying on Rule 144 does not know of any undisclosed material adverse information about the issuer.
An insider of AVAH filed a notice of proposed sale of 38,000 shares of common stock through Morgan Stanley Smith Barney on the NASDAQ, with an aggregate market value of
The shares to be sold come from a larger block of 108,963 restricted shares that vested on
Aveanna Healthcare Holdings Inc. (AVAH) received an updated ownership report on a Schedule 13G/A. Several J.H. Whitney–affiliated entities disclosed beneficial ownership of Aveanna common stock as of 12/31/2025.
PSA Healthcare Investment Holding LLC reported beneficial ownership of 15,523,810 shares, or 7.43% of the common stock. J.H. Whitney VII, L.P. reported 19,292,787 shares, or 9.23%. PSA Iliad Holdings LLC reported 1,426,034 shares (0.68%), JHW Iliad Holdings LLC reported 3,460,515 shares (1.66%), and JHW Iliad Holdings II LLC reported 362,746 shares (0.17%).
Each reporting person has sole voting and dispositive power over its reported shares and no shared power. The J.H. Whitney entities and funds and entities advised by Bain Capital Investors, LLC are parties to a stockholders’ agreement to coordinate voting for director nominees and transfers of Aveanna common stock. Based on available information, that broader group may be deemed to beneficially own about 121,666,770 shares, or 58.24% of Aveanna’s common stock under applicable rules, though the J.H. Whitney parties expressly disclaim beneficial ownership of shares held by others.
Aveanna Healthcare Holdings Inc. filed a current report describing new financial outlook information. On January 14, 2026, the company issued a press release updating its full year guidance for fiscal 2025 and announcing its full year guidance for fiscal 2026. The guidance details are contained in a press release furnished as Exhibit 99.1 and a January 2026 investor presentation furnished as Exhibit 99.2. These materials are provided for informational purposes under Items 2.02 and 7.01 and are treated as “furnished,” not “filed,” under securities laws.
Aveanna Healthcare Holdings (AVAH) filed an 8-K announcing a Second Amendment to its Amended and Restated Stockholders Agreement and a Board change. The amendment limits executive stock transfers: any sale or transfer of common shares by covered executives requires prior approval by the Compensation Committee and must keep each executive in compliance with the Company’s Stock Ownership Guidelines. “Sell to cover” transactions for exercise price or tax withholding are exempt. The amendment also permits certain Other Stockholders to transfer shares without restriction or consent.
Separately, Christopher Gordon resigned as a Class II director, stating no disagreement with the Company. The Board appointed Sam Weil (age 35), a Bain Capital Principal, as a Class II director and member of the Compensation Committee, serving until the 2026 Annual Meeting. The Board determined he is independent under SEC and Nasdaq rules, and as a Bain affiliate he will not receive director compensation.
Aveanna Healthcare Holdings Inc. (AVAH) furnished an investor presentation under Regulation FD. On November 7, 2025, the company made a financial presentation available to investors, attached as Exhibit 99.1 to an 8‑K.
The materials are also posted in the Investors section of aveanna.com. The company states it uses its website to distribute important and time‑critical information. The information in Item 7.01, including Exhibit 99.1, is furnished and not filed, and is not subject to Section 18 liabilities or incorporated by reference unless specifically stated.
Aveanna Healthcare Holdings (AVAH) reported stronger quarterly results for the period ended September 27, 2025. Revenue reached $621.9 million, up from $509.0 million a year ago, and operating income rose to $53.6 million. Net income was $14.1 million (basic EPS $0.07; diluted $0.06), compared with a loss last year. For the nine-month period, revenue was $1.77 billion and net income was $46.3 million.
Liquidity and balance sheet improved. Cash from operations was $76.1 million for the nine months, ending cash at $145.9 million. Stockholders’ equity turned positive to $9.2 million from a deficit at year-end 2024. The company refinanced into $1,325.0 million of term loans maturing in 2032 at a 7.89% rate, repaid the $415.0 million second lien loan, and recorded a $5.9 million loss on extinguishment and $16.0 million debt modification expense.
Strategic actions and funding. Aveanna closed the Thrive Skilled Pediatric Care acquisition with total consideration of $75.7 million, including 11.2 million shares valued at $59.8 million and preliminary goodwill of $61.8 million. The receivables Securitization Facility balance was $165.0 million at a 7.00% rate, with the maximum increased to $275.0 million. Shares outstanding were 208,911,373 as of September 27, 2025.
Aveanna Healthcare Holdings Inc. (AVAH) furnished an 8-K announcing it issued a press release with financial results for the three and nine-month periods ended September 27, 2025. The press release is provided as Exhibit 99.1 and relates to Item 2.02 (Results of Operations and Financial Condition), with related information also referenced under Item 7.01 (Regulation FD).
The company states the information in this report, including Exhibit 99.1, is “furnished” and not “filed,” which means it is not subject to Section 18 liabilities and will only be incorporated by reference in other filings if specifically stated. The filing is signed by the Chief Accounting Officer as of November 6, 2025.
Aveanna Healthcare (AVAH) — Form 4 insider transaction: On 10/24/2025, Director and 10% Owner Paul R. Vigano reported sales by affiliated entities pursuant to the option to purchase additional shares in an underwritten secondary offering. J.H. Whitney VII, L.P. sold 1,251,909 shares at $9; JHW Iliad Holdings LLC sold 224,553 shares at $9; and JHW Iliad Holdings II LLC sold 23,538 shares at $9.
Following these trades, reported indirect holdings include 19,292,787 shares via J.H. Whitney VII, L.P.; 15,523,809 via PSA Healthcare Investment Holdings LLC; 3,460,515 via JHW Iliad Holdings LLC; 1,426,034 via PSA Iliad Holdings LLC; and 362,746 via JHW Iliad Holdings II LLC.
Aveanna Healthcare Holdings (AVAH) insider transaction: On October 24, 2025, J.H. Whitney VII, L.P. reported the sale of 1,251,909 shares of common stock at $9.00 per share, coded "S", executed in an underwritten secondary offering.
Following the transaction, beneficial holdings reported include 19,292,787 shares indirectly through J.H. Whitney VII, L.P.; 15,523,809 shares indirectly through PSA Healthcare Investment Holdings LLC; and 1,426,034 shares indirectly through PSA Iliad Holdings LLC. The filing notes that certain affiliated entities may be deemed to share voting and dispositive power over these shares, with customary disclaimers of beneficial ownership beyond pecuniary interest.